CMC Biologics A/S Announce Manufacturing Agreement with Symphogen A/S
12-Aug-2008
"We are pleased to establish such a partnership with Symphogen and are excited to be involved in this unique field of recombinant polyclonal antibody technology," said Mads Laustsen, CEO of CMC.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.